ask why

Latest research

Every new paper in 280 characters, with how strong the evidence is and what readers question about it. Free to read.

Infectious diseases · Lancet Microbe · 2026-06-08

In 199 Ethiopian adults with uncomplicated P falciparum malaria, day-28 PCR-corrected ACPR was 96·8% with artemether-lumefantrine+primaquine and 98·9% with pyronaridine-artesunate+primaquine (96·5% at day 42). Not powered to compare arms; no serious adverse events.

RCTn = 199
Bezabih et al. Evaluation of the effectiveness of artemether-lumefantrine and artesunate-pyronaridine each combined with single low-dose primaquine in adults with Plasmodium falciparum infection in Ethiopia: a phase 2/3, observer-masked, randomised, parallel-group trial
Infectious diseases · Lancet Microbe · 2026-06-08

In Ethiopian adults with P vivax malaria (162 analysed), day-28 ACPR was 98.7% with chloroquine + low-dose primaquine and 98.8% with pyronaridine-artesunate + low-dose primaquine; no serious adverse events. Substudy: only the latter fully blocked mosquito infection by day 1.

RCTn = 176
Bezabih et al. Efficacy of chloroquine plus low-dose primaquine and pyronaridine-artesunate plus low-dose primaquine against Plasmodium vivax malaria in adults and transmission to mosquitoes in Ethiopia: a phase 2/3, observer-masked, randomised, parallel-group trial
Infectious diseases · Lancet Infect Dis · 2026-02-11

In an RCT of 960 adults with P vivax malaria and normal G6PD, unsupervised 7-day high-dose primaquine did not significantly reduce 6-month recurrence vs 14-day low-dose (13.0% vs 18.5%; HR 0.66, p=0.063). Secondary: single-dose tafenoquine 12.6% (HR 0.64).

RCTn = 960
Degaga et al. Effectiveness and safety of 7-day high-dose primaquine and single-dose tafenoquine versus 14-day low-dose primaquine in patients with Plasmodium vivax malaria (EFFORT): a multicentre, open-label, randomised, controlled, superiority trial

Sign in to react

Enter your email and we send a 6-digit code and a link. No password.

Your name and role

These appear beside any methods concern you post and on your profile page.